IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
FAIL · Does not pass the screen
31.24 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price31.24 USD at the 6 Nov 2026 close
Our value readUndervalued vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 3.51, read 2026-11-03
Ethical does not pass the values gate
Price31.24 USD
Fair value51.00
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-02Read Markdown38.86-19.6% to today ✓Accumulation gives way to Markdown after a 7% slide in 4 weeks
2026-09-01Read Accumulation41.58-24.9% to today Markup gives way to Accumulation after a 15% rise in 4 weeks
2026-08-02Read Markup36.01-13.2% to today Accumulation gives way to Markup after a 24% rise in 4 weeks
2026-07-02Read Accumulation28.98+7.8% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
IDEAYA Biosciences, Inc. holds its Markdown at $31.24. The statistical read favours the sellers, held for 4 days.
As held on the ledger · 2026-11-06
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 4 days
Price at the screen
$31.24
Valuation
N/A trailing · -7.93 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.08
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.52%
Below 33%
Interest-bearing debt is just 2.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
36.99%
Below 33%
Interest-bearing cash and securities are 37.0% of assets, above the one-third limit.
Fail
Receivables
10.71%
Below 49%
Money owed to the company is 10.7% of assets, under the 49% limit.
Pass
Revenue purity
20.86%
Below 5%
20.9% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
IDEAYA Biosciences,'s business is fine, but its cash and interest-bearing securities are about 37% of its assets, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when IDYA's ethical verdict changes
Today IDYA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 40% discount to our $51.00 fair value.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 38.7% discount to the base estimate.
Where our models see it going: fair-value estimate $51.00, with a range of $31.00 to $61.30, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Precision cancer drugs meet heavy losses and thin data
A company racing to match the right tumour to the right pill sounds clever on paper, yet the balance sheet tells a different story. IDEAYA is still posting a 62 percent negative profit margin and negative 14 percent return on equity, with a forward price to earnings ratio that sits in negative territory because earnings have yet to appear. Our screen clears it on ethics, but the opportunity rating stays at none.
Fourteen analysts cluster around a 50 dollar target, yet that view rests on early stage assets whose commercial path remains unproven. Unknown competitive moat and ongoing cash burn leave little margin for the usual biotech setbacks such as trial delays or regulatory pushback.
The real risk sits in the classic early stage trap: a low multiple that simply reflects absent profits rather than any bargain. Currency, dilution and clinical failure could all widen the gap between today's price and any eventual payoff. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IDYA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-07Markdown$31.24+1.9%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-06Markdown$30.65-5.3%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Markdown$32.36+3.3%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markdown$31.33-1.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$31.64-1.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$31.96+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$31.96-9.9%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter.
2026-10-25Markdown$35.47+3.5%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter.
2026-10-18Markdown$34.26-11.8%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52. Insiders have been net sellers over the past quarter.
2026-10-02Markdown · changed$38.86-6.5%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (16 analysts) rates it strong buy, with a mean price target of $52.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
